Filing Flows › Comparisons › KROS vs ZVRA
Keros Therapeutics vs Zevra Therapeutics: KROS and ZVRA compared
Keros Therapeutics is the larger company: $40.0M of revenue in its latest quarter (Q3 2026) against $37.8M for Zevra Therapeutics (Q3 2026). Keros Therapeutics is growing faster (+183% against +45% a year earlier). Keros Therapeutics is more profitable, with an operating margin of 32.0% against 30.7%.
Where the money goes: KROS and ZVRA
Keros Therapeutics (KROS) · Q3 2026
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
Zevra Therapeutics (ZVRA) · Q3 2026
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
| Keros Therapeutics (KROS) | Zevra Therapeutics (ZVRA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $40.0M | $37.8M |
| Revenue growth, Y/Y | +183% | +45% |
| Operating margin | 32.0% | 30.7% |
| Net earnings | $14.2M | $19.2M |
| Net margin | 35.4% | 50.9% |
| Operating cash flow | $3.4M | $10.0M |
| Free cash flow | $3.3M | $9.8M |
| Market value | — | $636M |
| P/E | — | 8.5× |
| Analysts’ mean target | — | $25.25 |
Questions
Which is bigger, Keros Therapeutics or Zevra Therapeutics?
Keros Therapeutics is the larger company: $40.0M of revenue in its latest quarter (Q3 2026) against $37.8M for Zevra Therapeutics (Q3 2026).
Is Keros Therapeutics or Zevra Therapeutics growing faster?
Keros Therapeutics is growing faster (+183% against +45% a year earlier).
Which is more profitable, Keros Therapeutics or Zevra Therapeutics?
Keros Therapeutics is more profitable, with an operating margin of 32.0% against 30.7%.
More: Keros Therapeutics earnings · how Keros Therapeutics makes money · Zevra Therapeutics earnings · how Zevra Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.